Therefore, the combined treatment with CDDP and specific inhibitors for IGF2BP3 or m6A, can be considered in a clinical setting to overcome intrinsic or acquired resistance to CDDP in bladder cancer patients. Here, IGF2BP3 is linked to urinary bladder carcinoma.